African countries face key challenges in the deployment of GM crops due to incongruities in the processes for effective and efficient commercial release while simultaneously ensuring food and environmental safety. Against the backdrop of the preceding scenario, and for the effective and efficient commercial release of GM crops for cultivation by farmers, while simultaneously ensuring food and environmental safety, there is a need for the close collaboration of and the interplay between the biosafety competent authorities and the variety release authorities. The commercial release of genetically modified (GM) crops for cultivation requires the approval of biosafety regulatory packages. The evaluation and approval of lead events fall under the jurisdiction of competent national authorities for biosafety (which may be ministries, autonomous authorities, or agencies). The evaluation of lead events fundamentally comprises a review of environmental, food, and feed safety data as provided for in the Biosafety Acts, implementing regulations, and, in some cases, the involvement of other relevant legal instruments. Although the lead GM event may be commercially released for farmers to cultivate, it is often introgressed into locally adapted and farmer preferred non-GM cultivars that are already released and grown by the farmers. The introduction of new biotechnology products to farmers is a process that includes comprehensive testing in the laboratory, greenhouse, and field over some time. The process provides answers to questions about the safety of the products before being introduced into the environment and marketplace. This is the first step in regulatory approvals. The output of the research and development phase of the product development cycle is the identification of a safe and best performing event for advancement to regulatory testing, likely commercialization, and general release. The process of the commercial release of new crop varieties in countries with established formal seed systems is guided by well-defined procedures and approval systems and regulated by the Seed Acts and implemented regulations. In countries with seed laws, no crop varieties are approved for commercial cultivation prior to the fulfillment of the national performance trials and the distinctness, uniformity, and stability tests, as well as prior to the approval by the National Variety Release Committee. This review outlines key challenges faced by African countries in the deployment of GM crops and cites lessons learned as well as best practices from countries that have successfully commercialized genetically engineered crops.
Martin et al.: Prospective evaluation of the impact of potent antiretroviral therapy on the incidence of Kaposi's Sarcoma in East Africa: findings from the International Epidemiologic Databases to Evaluate AIDS (IeDEA) Consortium. Infectious Agents and Cancer 2012 7 (Suppl 1):O19.
The tools of genetic engineering and modern biotechnology offer great potential to enhance agricultural productivity, food and nutritional security, and livelihoods of millions of smallholder farmers in Africa. Large and long-term investments have been made in several countries in Africa to access, develop, and commercialize safe biotechnology crops derived through modern biotechnology. This chapter presents case studies of biotechnology applications and progresses achieved in six countries in Sub-Saharan Africa including Burkina Faso, Ethiopia, Kenya, Malawi, Nigeria, Sudan, and Uganda targeting to address biotic and abiotic constraints faced by smallholder farmers and malnutrition. Based on the past 20 years of experience, the chapter identifies constraints, challenges, and opportunities for taking safe biotechnology crops to smallholder farmers in Africa.
It has been over five years since the first report of an outbreak of the fall armyworm, Spodoptera frugiperda (J.E. Smith) (Lepidoptera: Noctuidae) in Africa. The highly invasive pest, native to the Americas, has since spread across the African continent attacking many crops and causing significant yield loss to Africa’s staple crop, maize. From the onset of the outbreak, there have been massive and varied responses from farmers, governments and nongovernmental organizations. This mini-review provides various perspectives on S. frugiperda control in sub-Saharan Africa, building on previously published evidence, and experiences of the authors. It also highlights new technologies and lessons learned so far from the S. frugiperda outbreaks in sub-Saharan Africa, based on which suggestions on possible integrated management approaches are proffered.
Agricultural biotechnology is enhancing agricultural productivity, food security, and livelihoods globally. Some developing countries have established functional biosafety regulatory systems and have commercialized genetically modified (GM) crops. Release of GM crops requires enhanced capacity for regulatory compliance and product stewardship to help ensure sustainable use of biotechnology products. We conducted a survey of 66 stakeholders, mostly from Africa and Asia, in two-week international agricultural biotechnology short courses. Respondents showed knowledge of biotechnology benefits and expressed potential barriers to commercialization. They identified 16 crops in the "pipeline for commercialization." Stakeholders also shared ideas about how to build capacity for product stewardship. Product stewardship is a concept which requires each person in the product life cycle-innovators, scientists, and technology users, to share responsibility. This paper focuses on adoption of product stewardship for post-release management of GM crops which encompasses trait performance, resistance management, integrated pest management (IPM), good agricultural practices, high-quality seeds and planting material, intellectual property management, labeling, identity preservation, consumer acceptance, and effective marketing.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.